Talazoparib manufacturer and drug description

Talazoparib, an innovativePARP inhibitor, has brought new treatment prospects to patients around the world. It successfully blocks the DNA damage repair process by inhibiting the activity of poly-ADP-ribose polymerase, thereby promoting the apoptosis of tumor cells. This unique mechanism allows talazoparib to exhibit significant efficacy in the treatment of breast cancer and prostate cancer.

Pfizer, as the developer and manufacturer of talazoparib, relies on its leading position in the global biopharmaceutical field to ensure the high quality and safety of the drug. Sincethe U.S. Food and Drug Administration (FDA) approved talazoparib for the treatment of breast cancer on October 16, 2018, its efficacy and safety have been widely recognized around the world.

On June 20, 2023, the FDA once again approved the new indication of talazoparib, which is the treatment of metastatic castration-resistant prostate cancer in combination with enzalutamide. This new development further solidifies his position in the field of cancer treatment. In the TALAPRO-2 trial, the combination of talazoparib and enzalutamide performed well in terms of radiation progression-free survival, reducing the risk of disease progression or death by 55% compared with placebo plus enzalutamide.

In addition, the safety of talazoparib has been fully verified in clinical trials. Patients experience fewer and controllable adverse reactions during use, which allows patients to better tolerate the treatment and continue to benefit. However, as a prescription drug, talazoparib must be used under the guidance of a doctor. Patients should fully understand the drug's mechanism of action, indications, usage and dosage, precautions and other information before use, and communicate with the doctor regularly during use to ensure the safety and effectiveness of the treatment.

Currently, talazoparib is not available in China and patients need to purchase it from overseas. Although original drugs are priced higher, generic drugs are slightly cheaper, providing patients with more choices. When choosing drugs, patients should make reasonable choices based on their own financial situation and needs. No matter which drug is chosen, patients should undergo standardized treatment under the guidance of a doctor to obtain the best effect.